Companion Diagnostics and Cancer Biomarkers miR-148 b Functions as a Tumor Suppressor in Pancreatic Cancer by Targeting AMPK a 1
Gang Zhao,Jun-Gang Zhang,Yang Liu,Qi Qin,Bo Wang,Kui Tian,Lin Liu,Xiang Li,Yi Niu,Shi-Chang Deng,Chun-You Wang
2013-01-01
Abstract:miRNAs are small noncoding RNAs that participate in a variety of biologic processes, and dysregulation of miRNA is always associated with cancer development and progression. Aberrant expression of miR-148b has been found in some types of cancer, but its expression and potential biologic role in pancreatic cancer are still largely unknown. In this study, our data showed thatmiR-148bwas significantly downregulated in 48 pairs of human pancreatic cancer tissues and five cell lines. Furthermore, the deregulated miR-148b was correlated with increased tumor size, late tumor–node–metastasis stage, lymphatic invasion, distant metastasis, and worse prognosis in pancreatic cancer. Functional studies indicated overexpression of miR-148b dramatically suppressed the growth of cancer cells, attributable to induction of apoptosis and cell-cycle arrest at S-phase. Meanwhile, miR-148b remarkably inhibited invasion and enhanced chemosensitivity of pancreatic cancer cells. Moreover, ectopic expression of miR-148b was able to inhibit tumorigenicity in nude mice. Further studies revealed that AMPKa1 might be the direct target gene of miR-148b, and overexpressed AMPKa1 inversely correlated with miR-148b in pancreatic cancer. Silencing of AMPKa1 with RNA interference inhibited the growth of pancreatic cancer cells in vitro and in vivo and also induced apoptosis, cell-cycle arrest, and inhibited invasion of cancer cells,which is consistentwith the effects ofmiR-148b overexpression. In conclusion, miR-148b can inhibit cell proliferation, invasion, and enhance chemosensitivity of pancreatic cancer by targeting AMPKa1. Our present results implicate the potential effects of miR-148b on prognosis and treatment of pancreatic cancer. Mol Cancer Ther; 12(1); 1–11. 2012 AACR.